Abatacept in the Treatment of Uveitis

Oregon Health & Science University (OHSU)

Status and phase: Completed; Phase 2

Conditions: Uveitis

Treatments: Drug: Abatacept

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT01279954

e7035

Details and patient eligibility

About

The purpose of this study is to assess the safety and efficacy of abatacept in the treatment of uveitis.

Enrollment: 10 patients

Sex: All

Ages: 6+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients with vision-threatening autoimmune uveitis
• failure to respond to prednisone and at least one other systemic immunosuppressive, or intolerance to such medications due to side effects

Exclusion criteria

• serious concomitant illness that could interfere with the subject's participation

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

10 participants in 2 patient groups

open-label abatacept first, then 5 mg/kg abatacept

Experimental group

Description:

10 mg/kg abatacept (6 months). Then 5 mg/kg abatacept (18 months)

Treatment:

Drug: Abatacept

open-label abatacept first, then 10 mg/kg abatacept

Experimental group

Description:

10 mg/kg abatacept (6 months). Then 10 mg/kg abatacept (18 months)

Treatment:

Drug: Abatacept